In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner.
Isis Pharmaceuticals (NASDAQ: ISIS) takes on LINN Energy (NASDAQ: LINE) for this first round-robin match up in our search for the better stock today.
David Williamson, Motley Fool health care analyst, thinks Isis should advance to the next round because of one big reason -- its amazing drug pipeline. Wall Street heralds it as the best in biotech and puts Isis in play as a takeover target. A virtual who's who of big pharma has struck partnership deals. Isis already has orphan drug Kynamro on the market, and has seen recent success from a mid-stage study for an anti-clotting drug. A recent sell-off has given investors a chance to get this deep pipeline at a discounted price.
Joel South, energy analyst at The Motley Fool, thinks LINN Energy is the premier upstream MLP and worth of your investment. LINN offers a top tier distribution yield of 9.7% and management continues to execute on its strategy of acquiring mature oil and gas assets that are operated strategically to increase cash flows and return excess cash to unitholders.
Warren Buffett vs. His Worst Nightmare
Warren Buffett just called this emerging technology a "real threat" to his biggest cash-cow. While Buffett shakes in his billionaire-boots, only a few investors are embracing this new market which experts say will be worth over $2 trillion. It won't be long before everyone on Wall Street wises up, that's why The Motley Fool is releasing this timely investor alert. Click here to learn more about what's keeping Buffett up at night and the one public company we're calling the "brains behind" the technology.
Vote here to determine the winner of this match and sound off in the comments. Check back to Fool.com to see who advances in the tournament.
David Williamson has no position in any stocks mentioned. Joel South has no position in any stocks mentioned. The Motley Fool recommends Isis Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.